(Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs ...

Matchpoint Therapeutics partners with Novartis to develop oral covalent inhibitors for inflammatory diseases, with potential ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

Swiss pharma major Novartis (NOVN: VX) has entered into an exclusive option and license deal with Matchpoint Therapeutics to ...

Novartis and Matchpoint Therapeutics have entered into a partnership worth $1bn to develop oral inhibitors for inflammatory ...

Matchpoint Therapeutics has entered into an exclusive option and license agreement with Novartis to develop and commercialize oral covalent inhibitors.

A roundup of global health news reveals rising challenges, including Brazil's bird flu outbreak, vaccine policy changes by ...

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck small research deals.

European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...

The health sector sees significant developments as Edwards Lifesciences raises sales forecast due to strong demand for heart devices, while Bavarian Nordic enters potential takeover talks. Moreover, ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...